CorMedix Inc. CRMD
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
CorMedix Inc. (CRMD) is a healthcare company listed in the US with a market value of about $371M. In the twelve months to September 30, 2026 it had revenue of $412M and net income of $64M, a net margin of 15.5%.
Its overall Stock Analiz score is 3.0 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 7.3, a price to free cash flow of 1.2, 5-year revenue growth of 320% a year, a 5-year average ROIC of -30%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.
About CorMedix
CorMedix is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $189274 in 2014 to $312M in 2025, growth of about 96.1% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 99% over three years (dilution for shareholders). It spends 6% of revenue on research and development.
Score: 3.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Pays a dividend
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $412M | $312M | $43M | — | $65408 | $190936 | $239231 | $283266 | $429797 | $329327 | $224105 |
| Net income | $64M | $163M | -$18M | -$46M | -$30M | -$28M | -$22M | -$16M | -$27M | -$33M | -$25M |
| Free cash flow | $308M | $173M | -$51M | -$39M | -$25M | -$23M | -$22M | -$15M | -$24M | -$29M | -$22M |
| EPS (diluted) | $0.64 | $2.04 | $-0.30 | $-909.99 | $-739.99 | $-749.99 | $-769.99 | $-1799.99 | $-1509.99 | $-2999.98 | $-3249.00 |
| Net margin | 15.5% | 52.3% | -41.2% | — | -45409.9% | -14774.7% | -9207.7% | -5801.3% | -6242.4% | -10023.4% | -10996.5% |
| ROIC | — | 29.0% | -24.3% | -54.6% | -53.8% | -44.2% | -48.7% | -67.9% | -430.1% | -361.6% | -109.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $13.80, 196% above the current price; targets range from $12.00 to $17.00; the consensus rating is “Buy”; expected EPS is $0.43 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is CorMedix’s P/E ratio?
About 7.3, based on the last twelve months of diluted earnings per share.
Is CorMedix stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does CorMedix pay a dividend?
Not currently.
Is CorMedix a good stock to buy?
We do not give buy or sell advice. CorMedix scores 3.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.